FY2026 Earnings Forecast for BioSyent Issued By Bloom Burton

Key Points

• Bloom Burton has raised its FY2026 earnings forecast for BioSyent to $0.87 per share, reflecting optimism about the company's financial performance compared to the previous estimate of $0.86.
• BioSyent recently announced a quarterly dividend of $0.05 per share, which will be paid on September 15th, representing an annualized yield of 1.7%.
• The stock is currently trading at C$12.10, with a market cap of C$138.39 million and a price-to-earnings ratio of 19.64.

BioSyent Inc. (CVE:RX - Free Report) - Analysts at Bloom Burton upped their FY2026 earnings per share (EPS) estimates for BioSyent in a research report issued on Monday, August 25th. Bloom Burton analyst D. Martin now forecasts that the company will earn $0.87 per share for the year, up from their previous estimate of $0.86. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent's FY2027 earnings at $0.95 EPS.

BioSyent Stock Down 0.5%

Shares of RX stock traded down C$0.07 during trading hours on Thursday, reaching C$12.00. The company had a trading volume of 2,423 shares, compared to its average volume of 4,169. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. BioSyent has a twelve month low of C$9.20 and a twelve month high of C$12.49. The company has a market capitalization of C$135.13 million, a P/E ratio of 16.90 and a beta of 0.45. The stock's fifty day simple moving average is C$11.63 and its 200 day simple moving average is C$11.28.

BioSyent Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 1.7%. BioSyent's dividend payout ratio is currently 26.76%.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.